Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biogen Idec Inc Raises FY 2013 Guidance


Monday, 28 Oct 2013 07:15am EDT 

Biogen Idec Inc increased its fiscal 2013 guidance and expects revenue growth to be approximately 23% to 25%, Non-GAAP diluted EPS to be between $8.65 and $8.85 and GAAP diluted EPS to be between $7.50 and $7.70. The Company reported revenues of $5.5 billion in fiscal 2012. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $6.8 billion and EPS of $8.62 for fiscal 2013. 

Company Quote

303.81
-1.59 -0.52%
1:27pm EST